and no hypoglycemic episodes were observed.
transmission across at least three generations, similar phenotypes of the disease among all members of a family, and the C-peptide levels staying within the reference range for years [1] [2] [3] [4] . Confirmation of MODY is complicated and expensive, but enables to select the appropriate treatment and conduct genetic consulting [5, 6] . The real prevalence of MODY is unknown. According to CH Lachanse, around 1-2% of diabetes cases can be classified into this type [1] .
At present, it is known that a mutation in one of 13 genes can cause a certain subtype of the disease. Subtypes of MODY differ from each other by their prevalence, clinical picture, and treatment requirements [1, 7, 8] . Despite substantial variation in frequency of MODY subtypes in various populations, the most prevalent mutations affect genes of hepatocyte nuclear factor 1a (HNF1A) and glucokinase (GCK), which cause MODY3 and MODY2, respectively [9] . The proportion of these subtypes is up to 90% of all MODY cases [10] .
In some European countries, including the United Kingdom, the Netherlands, and Denmark, the most common form of monogenic diabetes is MODY3 (mutation of HNF1A), but in Spain, Italy, France, Germany, and the Czech Republic, the predominant form is MODY2 (mutation of GCK) [11] . The MODY subtypes 1-5 are the best-studied and most thoroughly described forms of the disease. The other subtypes are rare, and the data on their clinical features and treatment options are scarce.
In this report, we describe a case of MODY12, which is caused by a mutation in the ATP-binding cassette transporter sub-family C member 8 gene (ABCC8), encoding the sulfonylurea receptor 1 (SUR1).
CASE PRESENTATION
A 28-year-old Caucasian male, at initial examination in our clinic (September 2015) complained of a burning sensation and severe pain in the legs, numbness of toes, headache, and blurred vision. Diabetes was documented within four generations on the maternal side ( Fig. 1) . Diabetes manifested in all of them in the fourth or fifth decade of life, and all these subjects were treated by oral glucose-lowering agents. On the paternal side, there were cardiovascular diseases for two generations (coronary artery disease and sudden death).
On admission to our hospital in September 2015, the patient was taking glargine 13 U at night and insulin lispro 4 U before lunch and dinner (no injections were made before breakfast because of low glycemia). The total daily insulin dose was 0. Mutation Ala1457Thr in the gene ABCC8 was revealed in the proband. The substitution was confirmed by automatic Sanger sequencing. The revealed mutation at position 1457 of the ABCC8 protein is rare and causes a substitution of alanine with threonine (please see Fig. S1 in the supplementary material). The online software PolyPhen-2 (Polymorphism Phenotyping v2, Boston, Harvard, MA, USA), applied for prediction of protein structure [12] , showed high probability of an adverse effect of the Ala1457Thr mutation on the product of the ABCC8 gene (please see Fig. S2 in the supplementary material).
In the proband's mother, we revealed the same mutation in ABCC8 gene. Despite this, some phenotypic differences between proband and his mother were noted. In the mother arterial hypertension and mild fasting hyperglycemia (up to 8 mmol/L) was observed at the age of 30 years. Mild hyperglycemia was corrected successively on diet alone until Monitoring data on 4-7 days of gliclazide treatment are shown in Fig. 2 . Because of substantial amplitude of glucose excursions and a tendency to fasting hypoglycemia, further increase in gliclazide dose had seemed inappropriate. Thus, SGLT2 inhibitor dapagliflozin at 10 mg/day was added. On combined treatment glycemic excursions diminished, and no hypoglycemic episodes were detected by CGM (Fig. 3) .
The estimation of glucose variability (GV) at three therapeutic regimens, including insulin, gliclazide and gliclazide plus dapagliflozin, was performed. The GV parameters were derived [14, 15] . As shown in Table 1 , the notable decrease in GV parameters was achieved on gliclazide MR and dapagliflozin combination compared to preceding treatment with insulin and gliclazide MR alone. cause hyperinsulinemia in newborns [16, 17] . Besides, some ABCC8 mutations were revealed in subjects with neonatal diabetes [18] [19] [20] .
Recently a mutation in the ABCC8 gene within three generations of one family was reported; the phenotype resembles a deficiency of GCK (MODY2), with ''mild'' hyperglycemia that does not require pharmacotherapy [21] . It was demonstrated that ABCC8 mutations cause variable clinical phenotypes with glucose intolerance, overt diabetes, or insulin-requiring diabetes from a young age to adulthood. Several factors may explain this variability, also seen within families, such as the type and location of the mutation itself or other modifier genetic and superimposed environmental factors [22] . In our patient, we observed the relatively late clinical manifestation of diabetes (at age of 27 years) with a dramatic increase in glycemia to high levels. Surely, the latent course of the disease prior to clinical manifestation cannot be ruled out. In proband's mother, mild hyperglycemia was corrected successfully for a long time by diet alone. that impaired insulin secretion in response to glucose is a major metabolic feature in adult ABCC8 mutation carriers [22] . Diabetic patients with mutations in ABCC8 are usually responsive to treatment with sulfonylurea [18, 22] . In these patients, switching from insulin to sulfonylurea leads to the improvement of metabolic control [19] . Interestingly, that sulfonylurea in neonatal diabetes secondary to mutations in potassium-channel subunits produces measurable improvements in neuropsychomotor impairments, which are greater in younger patients [19, 24] . Furthermore, it was speculated that rather than a drug that targets both SUR1 and SUR2 isoforms, such as glibenclamide, a SUR1-specific drug, such as gliclazide, might influence neurological symptoms more effectively as only SUR1 isoforms are present in neuronal K ATP channels [18] . In our case, pilot treatment with gliclazide MR at an average therapeutic dose turned out to be effective, but was characterized by large glucose fluctuations and increased GV. A growing body of evidence suggests that high GV is a risk factor of diabetic vascular complications [15, 25] . Taking into account the rapid development of vascular damage in this patient, it seemed essential to prevent the episodes of both hypoglycemia and hyperglycemia and, thereby, to reduce GV. It was demonstrated recently that SGLT2 inhibitors decrease GV in patients with type 2 diabetes [26] and in type 1 diabetes [27] . We observed attenuation of glucose excursions and reduction of GV parameters on combined treatment with gliclazide MR and dapagliflozin in our patient with MODY.
Data on the use of SGLT2 inhibitors for the treatment of MODY are scarce. It was reported recently that dapagliflozin seems to be less efficient in MODY3 (HNF1A mutations) than in MODY2 (GCK mutations), that can be attributed to impaired SGLT2 function [28] . To the best of our knowledge, we provide here the first description of treatment with dapagliflozin in diabetes caused by mutation in the ABCC8
gene. The insulin-independent mechanism of action of SGLT2 inhibitors makes these agents a rather promising option for the treatment of patients with genetically mediated dysfunction of b-cells, who are not prone to ketoacidosis, especially when sulfonylurea effect is inappropriate.
CONCLUSION
The combination of MODY with prenatal brain impairment and epilepsy could be a phenotypic expression of a mutation in the ABCC8 gene, encoding SUR1. The combined therapy of sulfonylurea and SGLT2 inhibitors could be considered as a possible treatment option for patients with ABCC8-associated diabetes manifested at adulthood. Personalized diagnostics and treatment is essential for young subjects with non-classical diabetic forms.
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